Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Next Previous
Trial Profile

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Blinatumomab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Richter's syndrome
  • Focus Therapeutic Use
  • Acronyms BLINART; FILOCLL13-BLINART

Most Recent Events

  • 13 Dec 2022 Primary endpoint (Complete remission (CR) rate according to the revised Lugano criteria) has been met, according to results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 13 Dec 2022 Final results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 28 Oct 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top